Drugs Show Anti-Cancer Effects on Myeloma Cells
Source: Dr. Jonathan Aschoff
December 7, 2023 (Investorideas.com Newswire) These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Panbela Therapeutics Inc.'s (PBLA:NASDAQ) two polyamine inhibitors, ivospemin (SBP-101) and difluoromethylornithine (DFMO), were shown to inhibit multiple myeloma cells in vitro, a published analysis showed, Dr. Jonathan Aschoff, ROTH MKM analyst, reported in a December 4 research note.
"The data demonstrate that these agents as monotherapies have significant anti-cancer effects on multiple myeloma cell lines, which is increased when they are combined," Aschoff wrote.
4,067% Return Cited
Given the news, ROTH maintained its US$25 per share target price on Panbela, currently trading at about US$0.60 per share, noted Aschoff.
The difference between these prices implies a remarkable potential return for investors of 4,067%
The biopharma remains a Buy.
Minnesota-based Panbela and the University of Texas MD Anderson Cancer Center evaluated the effects of SBP-101 and DFMO on the growth and viability of four multiple myeloma cell lines: NCI-H929, RPMI-8226, ARP-1, and MM.1S. After exposing these to varying doses of the polyamine inhibitors individually and in combination, the researchers measured the effects on cell proliferation, cell viability, and the induction of apoptosis, or cell death. The doses used were based on clinical results of trials evaluating these compounds in other malignancies.
The resulting data were published in the November supplemental issue of Blood.
The objective was to determine if intervening at the polyamine synthesis stage would be effective as a multiple myeloma treatment. Investigating this approach is worthwhile because the proto-oncogene MYC, a significant cause of this cancer, influences the polyamine pathway and is tough to target directly.
Findings are Positive
The analysis revealed that both of Panbela's polyamine inhibitors decreased proliferation of cells in all four lines, Aschoff reported.
Specifically, as for SBP-101, one of the biopharma's lead assets, test results showed that increasing concentrations of it, from 1-10 micrometers (1-10 µM), significantly reduced cellular proliferation in all cell lines. The average percentages of cytotoxicity observed with SBP-101 10 µM were 84% in ARP-1, 69% in NCI-H929, 49% in MM.1S and 21% in RPMI-8226.
Regarding DFMO, increasing concentrations of it, from 1-100 µM, affected the cell lines as SBP-101 did. However, DFMO impacted RPMI-8226 the most versus ARP-1 with SBP-101. The percent of cell death resulting from DFMO 10 µM was 64% in RPMI-8226, 33% in NCI-H929, 28% in ARP-1, and 16% in MM.1S.
A combination of SBP-101 10µM and DFMO 100 µM completely stopped the growth of cells in all lines. Both monotherapy and combination therapy resulted in apoptosis.
Second Potential Approach
In other news, results of different research by Panbela and MD Anderson suggested that potential exists for a polyamine-targeted therapy in combination with CAR-T therapy.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/